Schonfeld Strategic Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-503,674	Closed	-$2.94M	–	2943
2022 Q4	$2.94M	Buy	503,674 +244,574	+94%	+$1.29M	0.02%	671
2022 Q3	$1.74M	Buy	259,100 +199,500	+335%	+$1.21M	0.01%	941
2022 Q2	$251K	Buy	+59,600	New	+$236K	﹤0.01%	1763
2019 Q2	–	Sell	-62,400	Closed	-$754K	–	1329
2019 Q1	$754K	Buy	+62,400	New	+$920K	0.03%	581
2017 Q2	–	Sell	-61,831	Closed	-$1.05M	–	824
2017 Q1	$1.05M	Sell	61,831 -28,169	-31%	-$338K	0.11%	248
2016 Q4	$926K	Buy	+90,000	New	+$823K	0.12%	242

Schonfeld Strategic Advisors's CNCE Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 503,674 shares — an estimated $2.94M sold.

Schonfeld Strategic Advisors first reported a position in CNCE in Q4 2016 and held it in 6 quarters. The position peaked at $2.94M in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Schonfeld Strategic Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 503,674 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.94M.
Schonfeld Strategic Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q4 2016 and held it in 6 quarters.
Schonfeld Strategic Advisors's Concert Pharmaceuticals, Inc. position peaked at $2.94M in Q4 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.